Melanotan II: research, legal status and who sells it
Melanotan II is a synthetic melanocortin agonist used for tanning. It was never approved, and case reports link it to serious harms.
By Editorial team. Updated Oct 14, 2026.
Awaiting expert review
This page is information, not medical advice. Melanotan II is not approved as a medicine in the markets below unless stated. We don't publish dosing or usage instructions.
- Also known as
- Melanotan II, MT-II
- Category
- Synthetic alpha-MSH analogue (unapproved tanning peptide)
- Evidence level
- Early human trials
- Price range
- $1.00/mg to $10.00/mg, median $3.50/mg across 60 vendors (compare)
- Our lab tests
- None yet (how testing will work)
Legal and regulatory status
| Where | Status |
| United States | Not FDA-approved; the nomination of melanotan II for pharmacy (503A) compounding was withdrawn after FDA flagged potential safety risks, and FDA plans to consult its compounding advisory committee on it before the end of February 2027 [1][2][14]. |
|---|
| United Kingdom | No UK-licensed medicine containing melanotan II appears in the MHRA products database [3]. |
|---|
| European Union | No medicine containing melanotan II is authorized in the EU, according to EMA's central and Article 57 product data [4][5]. |
|---|
| Canada | No product containing melanotan II appears in Health Canada's Drug Product Database [6]. |
|---|
| Australia | Schedule 4 (prescription-only) in Australia's Poisons Standard [7]. |
|---|
| Sport (WADA) | Not named on the 2026 Prohibited List; its section S0 bans any pharmacological substance with no current approval for human therapeutic use [8]. |
Summaries of official sources, checked Oct 14, 2026. Rules change; follow the source links. Not legal advice.
What it is
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) [9] and a non-selective melanocortin receptor agonist [10]. The approved drug bremelanotide (PT-141) was developed as an analogue of it [11].
Research status
Melanotan II was tested clinically for erectile dysfunction [11], and one early human trial was a 1996 pilot phase 1 study in three men [9]. It produced skin darkening, along with nausea, fatigue and drowsiness, and spontaneous erections [9]. Melanotan II never became an approved medicine [1]. Since then, unregulated use for tanning has generated case reports of melanoma, changes in existing moles and new atypical moles [12][13], as well as a case of kidney (renal) infarction [10]. FDA cites published case reports of melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism [2]. Conclusive evidence of a causal link is lacking, but reviewers stress that the substance is unlicensed and incompletely tested, so its risks are unknown [12][13].
Regulatory status
Melanotan II is not FDA-approved [1]. Its nomination for pharmacy compounding was withdrawn after FDA flagged these risks, and FDA plans to consult its compounding advisory committee on it before the end of February 2027 [2][14]. No melanotan II medicine is authorized in the UK, the EU or Canada [3][4][6]. Australia lists it in Schedule 4 (prescription-only) [7]. It is not named on WADA’s 2026 Prohibited List, although WADA’s section S0 bans substances with no current approval for human therapeutic use [8].
Quality and testing considerations
The UK medicines regulator has warned about the potential impurity of tanning products sold as melanotan and about blood-borne virus risks from needle sharing [15]. A dermatology review notes uncertainty about how unregulated melanotan products are prepared, and that multiple national health organizations have issued safety warnings [12].
Where it’s sold
Melanotan II is sold online as a “research use only” peptide; the tables below track listings.
Melanotan II compared
Melanotan II prices: cheapest listings
The five lowest $/mg listings out of 71. See all Melanotan II prices
Prices come from each vendor's public product feed and were last fetched Oct 15, 2026.
They exclude shipping and discounts. $/mg uses the labeled amount, not measured content. A transparency score marked * is based on fewer than six checks; checks we couldn't complete score 0. How we compare prices.
Sources
- Drugs@FDA: FDA-Approved Drugs (database searched by active ingredient). U.S. Food and Drug Administration. Accessed Oct 14, 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 April 2026). U.S. Food and Drug Administration. Accessed Oct 14, 2026
- MHRA Products: licensed-medicine search for "melanotan". Medicines and Healthcare products Regulatory Agency (UK). Accessed Oct 14, 2026
- EMA medicines data: centrally authorised human medicines (export of 14 October 2026). European Medicines Agency. Accessed Oct 14, 2026
- EMA Article 57 product data: medicines authorised in the EU/EEA (data as of 9 October 2026). European Medicines Agency. Accessed Oct 14, 2026
- Drug Product Database online query (searched by active ingredient). Health Canada. Accessed Oct 14, 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327, registered 30 September 2026). Federal Register of Legislation, Australian Government. Accessed Oct 14, 2026
- World Anti-Doping Code International Standard: Prohibited List 2026 (in force 1 January 2026). World Anti-Doping Agency. Accessed Oct 14, 2026
- Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences (1996). Accessed Oct 14, 2026
- Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN Case Reports (2020). Accessed Oct 14, 2026
- Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides (2006). Accessed Oct 14, 2026
- Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. International Journal of Dermatology (2017). Accessed Oct 14, 2026
- Melanoma associated with the use of melanotan-II. Dermatology (2014). Accessed Oct 14, 2026
- Meeting of the Pharmacy Compounding Advisory Committee (to be held before the end of February 2027). U.S. Food and Drug Administration. Accessed Oct 14, 2026
- Melanotropic peptides: more than just 'Barbie drugs' and 'sun-tan jabs'? British Journal of Dermatology (2010). Accessed Oct 14, 2026